Supernus Pharmaceuticals, Inc. (SUPN) Stake Decreased by Capital Management Corp VA

Capital Management Corp VA decreased its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 3.8% during the second quarter, Holdings Channel reports. The institutional investor owned 117,000 shares of the specialty pharmaceutical company’s stock after selling 4,660 shares during the period. Capital Management Corp VA’s holdings in Supernus Pharmaceuticals were worth $5,043,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Eqis Capital Management Inc. acquired a new position in Supernus Pharmaceuticals during the second quarter worth about $371,000. Meeder Asset Management Inc. increased its position in Supernus Pharmaceuticals by 3,455.2% in the second quarter. Meeder Asset Management Inc. now owns 2,382 shares of the specialty pharmaceutical company’s stock worth $103,000 after buying an additional 2,315 shares in the last quarter. State of Alaska Department of Revenue increased its position in Supernus Pharmaceuticals by 79.5% in the second quarter. State of Alaska Department of Revenue now owns 9,929 shares of the specialty pharmaceutical company’s stock worth $427,000 after buying an additional 4,399 shares in the last quarter. Creative Planning increased its position in Supernus Pharmaceuticals by 67.4% in the second quarter. Creative Planning now owns 18,254 shares of the specialty pharmaceutical company’s stock worth $787,000 after buying an additional 7,349 shares in the last quarter. Finally, NEXT Financial Group Inc acquired a new position in Supernus Pharmaceuticals during the second quarter worth about $640,000. Hedge funds and other institutional investors own 90.95% of the company’s stock.

Shares of Supernus Pharmaceuticals, Inc. (SUPN) traded down 5.20% during midday trading on Monday, reaching $41.95. 1,366,935 shares of the company’s stock traded hands. The stock has a market capitalization of $2.11 billion, a P/E ratio of 22.57 and a beta of 1.34. The firm’s 50-day moving average price is $38.15 and its 200 day moving average price is $30.48. Supernus Pharmaceuticals, Inc. has a 1-year low of $17.25 and a 1-year high of $44.95.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $0.19 EPS for the quarter, missing the consensus estimate of $0.22 by $0.03. Supernus Pharmaceuticals had a return on equity of 31.79% and a net margin of 42.46%. The firm had revenue of $57.58 million for the quarter, compared to analyst estimates of $57.91 million. On average, equities analysts predict that Supernus Pharmaceuticals, Inc. will post $1.01 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Supernus Pharmaceuticals, Inc. (SUPN) Stake Decreased by Capital Management Corp VA” was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.com-unik.info/2017/07/17/supernus-pharmaceuticals-inc-supn-stake-decreased-by-capital-management-corp-va.html.

A number of research firms have recently issued reports on SUPN. Piper Jaffray Companies downgraded shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $46.00 price objective on the stock. in a research note on Monday. Janney Montgomery Scott began coverage on shares of Supernus Pharmaceuticals in a research note on Friday. They set a “neutral” rating and a $47.00 price objective on the stock. Zacks Investment Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $49.00 price objective on the stock in a research note on Thursday. Cantor Fitzgerald increased their price objective on shares of Supernus Pharmaceuticals from $34.00 to $49.00 and gave the company a “buy” rating in a research note on Wednesday, July 5th. Finally, Jefferies Group LLC increased their price objective on shares of Supernus Pharmaceuticals from $45.00 to $51.00 and gave the company a “buy” rating in a research note on Wednesday, June 28th. Three analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $42.00.

In other Supernus Pharmaceuticals news, CFO Gregory S. Patrick sold 54,000 shares of the business’s stock in a transaction that occurred on Monday, April 24th. The shares were sold at an average price of $32.37, for a total transaction of $1,747,980.00. Following the completion of the transaction, the chief financial officer now owns 54,221 shares in the company, valued at approximately $1,755,133.77. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Padmanabh P. Bhatt sold 3,735 shares of the business’s stock in a transaction that occurred on Wednesday, July 12th. The stock was sold at an average price of $44.90, for a total transaction of $167,701.50. Following the transaction, the vice president now owns 21,209 shares of the company’s stock, valued at approximately $952,284.10. The disclosure for this sale can be found here. Insiders have sold a total of 90,097 shares of company stock valued at $3,095,503 in the last quarter. 6.70% of the stock is currently owned by company insiders.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

What are top analysts saying about Supernus Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Supernus Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit